Company intelligence / Profile preview

Innovative Targeting Solutions

Vancouver, British Columbia, Canadainnovativetargeting.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has developed a protein engineering platform called HuTARG for generating fully human antibody and T cell receptor-based therapeutics. The technology uses RAG1/RAG2 mediated V(D)J recombination to generate diversity in vitro[1][6].

Modalities: AntibodiesT cell receptor-based therapeuticsbiologics
Industry: Drug Discovery Services

Partnerships

A2 Biotherapeutics (co-founded in 2018)7 other pharma/biotech collaborations mentioned but not named specifically[1]

Beyond the preview

Go deeper on Innovative Targeting Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovative Targeting Solutions.

Explore the full profile